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Abstract
Purpose: A realistic description of visual symptoms associated with dry age-
related macular degeneration (AMD) is important for raising awareness of the
condition and educating patients. This study aimed to develop a set of descriptors
for dry AMD and examine the realism of images currently and frequently used to
show visual symptoms of the condition.
Methods: Volunteers with dry AMD with a range of disease severity were given
an eye examination and were asked to describe visual symptoms of their condi-
tion in a conversational interview. Participants were also asked to comment on a
photograph typically used to portray the visual symptoms of AMD. Interviews
were audio recorded, transcribed and subjected to content analysis.
Results: Twenty-nine participants were interviewed. Median (interquartile range
[IQR]) age was 75 (70, 79) years. Median (IQR) binocular visual acuity (VA) and
Pelli-Robson contrast sensitivity (CS) was 0.2 (0.18, 0.36) logMAR and 1.65 (1.50,
1.95) log CS respectively. Three, 17 and nine patients had early, intermediate and
late (geographic atrophy, GA) AMD, respectively. The most frequently reported
descriptor group was blur (n = 13) followed by missing (n = 10) and distortion
(n = 7). We chose the most popular image used to portray the visual symptoms
of dry AMD based on an internet search and showed this to 21 participants. Six-
teen participants (76% [95% confidence interval 53–92%]), including three out
of the seven people with geographic atrophy, unequivocally rejected the realism of
the image.
Conclusions: People with dry AMD use a wide range of descriptors for their visual
experience. Visual symptoms of dry AMD as portrayed by commonly shown
images were not the experience of most people in this study.
Introduction
Age-related macular degeneration (AMD) is the most com-
mon cause of visual impairment in developed countries; its
prevalence is set to increase as the population ages. For
example, 196 million people are estimated to have the con-
dition by 2020.1 AMD impacts negatively on patients’
visual ability and quality of life.2 Yet, disease awareness of
AMD in the public is limited.3–6 At the same time, many
people with early and intermediate AMD do not recognise
that they have the disease,7, 8 whilst others with more
advanced AMD are reported to be unaware of their
scotomas.9
Age-related macular degeneration can be divided into a
number of stages.10 Early and intermediate AMD are char-
acterised by yellow/white deposits (drusen) beneath the
retinal pigment epithelium, and areas of hyperpigmenta-
tion or hypopigmentation. Later stages may take one of
two forms: neovascular (wet or exudative) AMD, charac-
terised by growth of new blood vessels beneath the retina
with a tendency to leak, causing sudden vision loss, or geo-
graphic atrophy (GA), characterised by sharply demarcated
areas of hypopigmentation caused by atrophy, causing
more insidious vision loss.10, 11 Non- neovascular AMD
(i.e. early and intermediate AMD and GA) may also be
known as dry AMD, and comprises about 90% of
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diagnosed cases of AMD.12 A realistic description of visual
symptoms associated with dry AMD is important for rais-
ing awareness of the condition and educating patients; this
is the subject of our study.
A simple search on the internet will yield common depic-
tions of the visual symptoms of people with AMD. Typi-
cally, this will be a photograph with a grey or black patch
superimposed over its centre. A widely used example of this
is the National Eye Institute (NEI) photograph, ‘A scene as
it might be viewed by a person with age-related macular
degeneration’ (Figure 1).13 In this study, we aim to explore
the accuracy of these representations with respect to the
patient experience of people with early and intermediate
AMD and pre-end stage GA. In addition we ask patients to
develop a set of descriptors for visual symptoms of dry
AMD.
Methods
Images
To establish which images are used most frequently to
depict the vision of people with AMD, a Google Image
search was conducted independently by two of the authors
(LAE and DJT). The search term used was, ʽvision age
related macular degeneration’. The first 50 images pro-
duced by the search were evaluated and a description of
each image’s content was entered into a spreadsheet.
Participants
People with dry AMD were recruited from Moorfields Eye
Hospital NHS Foundation Trust (London), optometrists
local to City, University of London, and the membership of
the Macular Society (www.macularsociety.org). Eligibility
criteria required participants to be aged ≥60 years, have
sufficiently clear ocular media, adequate pupillary dilation
and fixation to allow quality fundus imaging (Lens Opaci-
ties Classification System [LOCS] III grade <3), and to have
dry AMD (early/intermediate/late) in their better-seeing
eye (assessed by best-corrected visual acuity [VA]). Fellow
eyes of patients were permitted to be of any AMD status
because the impact of the better eye has been found to have
a stronger relationship with vision related quality of life
than the worse eye.14–16 Binocular VA was required to be
0.7 logMAR or better (Snellen equivalent of 6/30, 20/100)
as measured using an Early Treatment Diabetic Retinopa-
thy Study (ETDRS) chart. Patients were excluded if they
had neovascular AMD in their better-seeing eye, had any
ocular or systemic diseases that could affect visual function
or history of medication known to affect macular function
(e.g. tamoxifen or chloroquine), or high risk of angle clo-
sure during pupillary dilation (Van Herick <Grade 2, his-
tory of angle closure or experience of prodromal symptoms
of angle closure). In addition patients were required to pass
an abridged version of the Mini Mental State Evaluation17,
18 and to have sufficient knowledge of the English language
to carry out the interview.
The study was approved by a National Health Service
(NHS) approved Research Ethics Committee and was con-
ducted according to the tenets of the Declaration of Hel-
sinki. Written, informed consent was obtained from each
participant prior to examination. Participant information
was anonymised before being entered into a secure com-
puter database.
Clinical examination and screening
All tests and interviews were conducted by an optometrist
(DJT). Structured history and symptoms were taken
including questions from the EQ-5D questionnaire19 to
Figure 1. Image frequently used for education about age-related macular degeneration (AMD). The image on the left shows ‘normal vision’ whilst
the image on the right shows ‘vision with AMD’. Source: https://nei.nih.gov/health/examples.
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assess general health. Best-corrected VA was determined
with subjective refraction to correct the full spherical and
astigmatic refractive error using a trial frame and a backlit
ETDRS chart (mean luminance of 204 cd m2) at 4 m
(mono- and binocularly). This was scored per letter (and in
logMAR format) and participants were encouraged to read
down the chart until they were unable to read three out of
a possible five letters on a line. Contrast sensitivity (CS)
was tested with the Pelli-Robson chart at 1 m (binocularly)
with best-corrected distance prescription (as described
above). This was scored per letter (if participants read ‘C’
instead of ‘O’ or vice versa this was counted as correct).
Following their interview, participants underwent dilated
fundus examination. Lens clarity was graded using the slit
lamp biomicroscope, according to the LOCS III grading
scale.20 Fundus imaging was conducted, including colour
fundus photography, Spectral Domain-OCT and fundus
autofluorescence. These were used to classify and grade
AMD status by better-seeing eye as early, intermediate or
late according to the Beckman classification scale.10 This
widely used scale grades macular disease according to dru-
sen size, pigmentary abnormalities and presence/absence of
GA or neovascular AMD.
Interviews and data analysis
The following questions were asked as part of a longer
interview about participants’ wider experiences with AMD.
Interviews were recorded using an audio recorder, tran-
scribed verbatim by an independent transcription company
and transcripts were checked by the interviewer (DJT).
Participants were asked, ‘When you are aware of your
AMD, can you describe how it looks?’ and, ‘How would
you describe what it is wrong or different about your vision
to someone without AMD?’
The analysis of the responses was similar to that
described elsewhere.21 In brief, transcribed responses to the
questions were read individually by two of the authors
(LAE and DJT) and words or phrases considered to be
descriptors of visual symptoms were highlighted. The
authors then compiled a list of individual descriptors.
Where one participant used the same descriptor multiple
times, this was counted as one occurrence of that descrip-
tor. Numbers of participants to use each descriptor were
then counted. A matrix was generated showing combina-
tions of descriptors used by each participant.
Participants were then given an A4 size page showing the
NEI photograph, in both its unaltered (i.e. ‘normal vision’)
and manipulated (i.e. ‘vision with AMD’) forms (Figure 1).
They were encouraged to hold the sheet at an angle and dis-
tance to allow for optimal viewing conditions for them to
see the images as clearly as possible. Participants were asked
to comment on how these images tie in with their
experiences. Care was taken to avoid asking the question in
a leading manner.
Two of the authors (DJT and LAE) independently read
through the transcribed responses and assessed whether the
response indicated that the image tied in with the patient’s
experience (‘YES’), whether it didn’t (‘NO’) or if the
answer was unclear (‘UNCLEAR’). Any disagreements were
arbitrated by another author (DPC). At the time of assess-
ment, both researchers were masked to the identities and
AMD severity of participants.
Results
A Google Images search for ‘vision age-related macular
degeneration’ was conducted independently by two of the
authors (DJT and LAE) on 27 March 2017. From the top
50 images produced by the search, 10 images (20%) were
the NEI photo of boys with a ball (Figure 1). Twenty-seven
(54%) were similar depictions of AMD with different pho-
tographs (i.e. a black or grey patch in the centre of an
image). The remaining 13 (26%) images were mainly dia-
grams of the eye or textual information about AMD.
Others included a photograph of a celebrity known to have
AMD and a poster for macular degeneration awareness.
There were no disagreements between the two independent
investigators for this exercise.
We repeated our Google Images search with a variety of
similar phrases: ‘how will age-related macular degeneration
affect my vision’; age-related macular degeneration sight’;
‘age-related macular degeneration eyesight’; ‘age-related
macular degeneration vision loss’; ‘age-related macular
degeneration symptoms’; ‘how does age-related macular
degeneration look’; ‘what do people with macular degener-
ation see’. A similar array of results was observed; at least
10% (and up to 26%) of the top 50 results consistently
showed the NEI image.
Twenty-nine patients were interviewed about how their
vision looks. The median (interquartile range [IQR]) age of
patients was 75 (70, 79) years. Median (IQR) binocular
VAand Pelli-Robson CS were 0.2 (0.18, 0.36) logMAR and
1.65 (1.5, 1.95) log CS, respectively. Better and worse eye
median (IQR) were 0.24 (0.20, 0.39) logMAR and 0.40
(0.30, 0.83) logMAR respectively. Three patients had early
AMD, 17 had intermediate AMD and nine patients had late
AMD (GA). Some descriptions given regarding vision loss
are shown in Table 1.
Thirty-one individual descriptors were identified. Syno-
nyms were grouped together, creating 10 descriptor groups.
Synonyms used to create descriptor groups are given in
Table 2. A large percentage of participants (45%) reported
their visual symptoms in a way that implied an experience
of blur. Visual distortions and missing parts of the image
were also commonly reported. The most common visual
© 2017 The Authors. Ophthalmic and Physiological Optics published by John Wiley & Sons Ltd on behalf of College of Optometrists. 3
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symptom reported by GA patients was ‘missing parts’
(n = 6) whilst the most common symptom reported by
patients with intermediate AMD was ‘blur’ (n = 8). Partici-
pants often reported more than one visual symptom. A
matrix showing descriptors used by each participant is
shown in Figure 2. Descriptors were considered a ‘primary
descriptor’ if they were the initial symptom mentioned by a
participant. All subsequent descriptors were considered
‘secondary descriptors’. For example, one participant
responded ‘I’ve noticed letters missing from exhibitions
particularly when I go. . . Slightly more hazy than it was . . .
Sometimes it’s difficult to distinguish colours that are very
similar’. In this instance ‘missing parts’ would be the pri-
mary descriptor, ‘blur’ and ‘colours difficult’ would be sec-
ondary descriptors. Use of multiple descriptors was most
common amongst people with GA. The most common pri-
mary descriptor amongst participants with intermediate
AMD was ʽblur’, whilst the most common primary descrip-
tor for those with GA was ʽdistortion’.
The interviewer felt it was inappropriate to show six par-
ticipants the NEI photograph because they had expressed
emotional distress at the prospect of their vision worsening;
this complied with the ethical aspects of the interview pro-
tocol. Two participants were unable to see either pho-
tograph adequately to make a judgement due to their poor
vision. Therefore, our assessment of response to the NEI
image (the photo of the boys) was restricted to 21 partici-
pants (three, 11 and seven respondents who had early,
intermediate and late [GA] AMD in their better-seeing eye,
respectively). Median (IQR) binocular VA and CS scores
for these 21 participants were 0.24 (0.20, 0.36) logMAR and
1.65 (1.35, 1.90) log CS respectively. Median (IQR) better
and worse eye VA scores were 0.22 (0.2, 0.36) and 0.46
(0.32, 0.92) logMAR respectively. Example responses are
shown in Table 3.
Only two participants reported the image to be a good
indication of their visual symptoms. One of these individu-
als had GA and a binocular VA of 0.32 (better eye 0.32 and
worse eye 0.40) logMAR and CS of 0.75 log units. The
other individual to report the NEI image to be a good indi-
cator of their visual symptoms had intermediate AMD and
binocular VA of 0.44 (better eye 0.4 and worse eye 0.8) log-
MAR and CS of 1.35 log units. Sixteen participants, repre-
senting 76% (95% confidence interval of 53–92%) of our
sample, clearly stated that the image did not represent their
visual symptoms. Three gave answers that were deemed to
be unclear. Table 4 shows the summary results for different
severities of AMD.
Discussion
Images showing a patch of distortion or blackness in cen-
tral vision surrounded by a clear periphery (Figure 1) are
frequently used illustrators of vision with AMD. Our survey
of a sample of images yielded from an internet search sup-
ports this observation – three quarters of images showed
virtually the same basic representation. However, only a
small number of our sample of people with dry AMD
reported this to be an accurate depiction of their visual
experience and this was a key finding from our study. Most
Table 1. Examples of descriptions of vision loss with descriptor words/
phrases in bold
AMD
Classification Description of vision
GA ‘Lampposts, sort of . . . bending. . .. . .As I’d gone on
looking at the wall now it’s got bricks in, I know I
can see – they’re sort of a bitwobbly. . ...I know
they’re straight really.’
‘It’s foggy all the time. . . that’s what I noticed first. I
used to be saying gosh, is it foggy today and he’d
say no, no.’
‘It’s like if I’m looking at a scene, something on
television or even out in the road, it’s – there’s part
of it missing. There’s part of it missing there. I
can’t see the whole picture anymore.’
Intermediate
AMD
‘I’m looking out from two discs that are
shimmering, like two little suns but not as bright..
they’re really shimmering. . ...like. . .gold.’
‘Well it’s things like when I was standing on the
station today, when you’re looking at a long
platform, it can look a wavy line.’
Early AMD ‘I’ve lived in [the same town] for 44 years so I should
know quite a lot of people but I never see them,
well not never but I don’t see acquaintances very
well because it’s a bit blurry.’
‘I don’t draw my curtains so I look outside and I can
see on the house opposite I see two chimneys
instead of one.’
Table 2. Words and phrases used by dry AMD patients to describe
vision. Descriptions considered to be synonyms of each other were
grouped together into descriptor categories
Descriptor
category Synonyms of descriptor
Blur Not clear, Out of focus, Fuzzy, Foggy, Hazy,
Misty, Cloud
Distorted Bendy, Crooked, Wavy, Wobbly, Wiggled
Missing part/s Black parts, Space, Patchy, Grey area, Words
dropping from page
Shiny area/s Flash, Sparkles, Spiral of light
Double vision
Dark Dull
Colours difficult
Speckled
Smeary
Bullseye
© 2017 The Authors. Ophthalmic and Physiological Optics published by John Wiley & Sons Ltd on behalf of College of Optometrists.4
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people in our study did not think these images represented
their visual symptoms. There was no strong evidence for
this depiction representing visual symptoms for those with
advanced dry AMD in the better-seeing eye either: only one
person out of seven with geographic atrophy stated that it
was clearly representative of their visual symptoms. From
this study we have also learnt that noticeable and
describable vision loss is not limited to those with neovas-
cular AMD or even just those with late AMD. This is an
important finding. For instance, people in our sample with
intermediate AMD provided a variety of descriptors of
their visual symptoms rather than saying they were asymp-
tomatic. Moreover, these descriptions were far more com-
plete and varied than those implied by images that are used
to depict the condition.
Our main findings are important for several reasons.
First, the images we have scrutinised in this study are
designed to educate the public about AMD and we have
shown they are not fit for this purpose. Second, the images
could be misinterpreted to be a sign of early visual changes
in AMD but this clearly does not fit with the experience of
people with early or intermediate AMD in our sample.
Third, the visual symptoms experienced by most people
with AMD are likely more subtle and less simplistic than
those depicted in the images; this could have ramifications
for individuals about misunderstanding the severity of their
own condition and may in turn affect adherence to man-
agement strategies such as self-monitoring of vision and
lifestyle changes to minimise risk of disease progression.
Our results show how heterogeneous descriptions of
vision loss in dry AMD can be. Thirty-one individual
descriptors, and 10 separate descriptor groups were identi-
fied. The most frequently used descriptor, ‘blurred vision’,
was only reported by half of our participants. Distortion,
which is often commonly associated with neovascular
AMD,22 was reported by participants with intermediate
AMD and GA in their better eye. Only two of these had
unilateral neovascular AMD in their worse eye. Moreover,
when participants reported multiple visual symptoms, there
was no obvious pattern of symptoms commonly occurring
together.
Previous research has highlighted the inaccuracy of
depicting peripheral vision as being a clear surround to a
patch of dysfunction in central vision. Visual acuity reduces
Figure 2. Matrix type chart showing descriptor categories reported by each participant. Each column shows descriptors from one participant. Rows
are organised by frequency of occurrences for each descriptor category across all participants; ‘blur’ was reported most frequently, followed by ‘miss-
ing part/s’ and ‘distorted’, whilst ‘speckled, ‘smeary’ and ‘bullseye’ were reported least frequently. Five columns are empty – these represent partici-
pants (one with early age-related macular degeneration (AMD) and four with intermediate AMD) who did not report any descriptors of visual
symptoms when asked.
Table 3. Example responses to the NEI image for participants who pos-
itively reported the NEI image to be a good indication of their visual
symptoms (top) and for those who stated that the NEI image did not
represent their visual symptoms (bottom). (AMD classification shown in
parentheses)
Is NEI image an accurate representation of vision with AMD?
Yes ‘Yes. . ..that’s quite a good indication. . .’ (GA)
‘Yes, that is it, the blurred one. . .’ (Intermediate AMD)
No ‘. . .nothing like that one. . .’ (Intermediate AMD)
‘Well I haven’t got anything at all like that. . .’ (GA)
‘That wouldn’t happen to me. . . the colours wouldn’t be there. . .’
(Intermediate AMD)
‘No. I don’t recognise that . . .’ (Intermediate AMD)
‘Well . . . absolutely not. . .., no relation to me at this
moment. . . So I’m quite pleased about that..’ (Early AMD)
Table 4. Number of participants reporting the NEI photograph was an
accurate representation of their vision (‘Yes’), did not depict their vision
(‘No’) and those whose responses were not clear (‘Unclear’). Totals from
the whole sample are represented as percentages (95% confidence
intervals [CI])
Is NEI image an accurate representation of vision with AMD?
AMD type Yes No Unclear
All (n = 21) 2 16 3
% (95% CI) 10 (1–30) 76 (53–92) 14 (3–36)
Early/intermediate AMD (n = 14) 1 13 0
Geographic atrophy (n = 7) 1 3 3
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with distance from the fovea and one paper has produced
illustrations theorising what a more realistic simulation of
macular disease may look like with a blurred, rather than
clear, periphery.23 However, the realism of these images is
thrown into question when one considers the fact that we
do not perceive our peripheral vision as blurred.24 Other
research has attempted to simulate central vision loss in
AMD using contact lenses with central opacities.25 Yet this
type of simulation cannot easily capture the real experience
of patients, where size and depth of scotoma may vary from
person to person.26 Whilst other studies have attempted to
build realistic representations of glaucomatous visual field
loss using reports from patients,19, 27 to our knowledge this
has not been attempted in AMD. Reports in the literature
on perceptions of vision loss in AMD tend to come from
descriptions made by individual patients.28, 29 No studies
have brought together reports from multiple patients.
Fletcher and colleagues9 did ask a large number of people
with AMD attending their initial low vision rehabilitation
evaluation whether they had experiences that led them to
believe that they had defects in their field of vision. Inter-
estingly, the majority of these patients were asymptomatic
but many reported experiences of items in their vision ʽdis-
appearingʼ; this observation is somewhat dissimilar to the
idea of a noticeable and constant disturbance in central
vision as depicted in the images we have scrutinised in this
study. Moreover our results indicated ʽmissing partsʼ was a
common description of the visual loss. Given the hetero-
geneity of the descriptors of visual symptoms reported in
our study, it is perhaps unlikely that vision in dry AMD
can be encompassed by a single image. It may be more
appropriate to develop a series of images or a dynamic rep-
resentation, perhaps a series of movies or digital media, to
more accurately depict vision in dry AMD. Future studies
might build on this idea.
Our experimental design was a study strength because
we have directly captured views from people with dry
AMD. Our image search experiment illustrated the ubiq-
uity of the NEI image. The remaining simulations of vision
in AMD found using our image search were, on the whole,
similar to the NEI image in that they depicted a black or
grey patch in the centre of a photograph. However, there
were some differences between these simulations; for exam-
ple some scotomas had a straight edge but the majority had
a gradual fade, some retained some detail within the area of
the scotoma, whilst others did not. It is possible that some
of these might be better representations of visual symptoms
in dry AMD than the NEI image.
One limitation of our study relates to lens opacities.
Although participants were excluded if they were graded ‘3’
or higher on any of the domains of the LOCS III scale,
there is a possibility that blur caused by minimal cataract
could have affected the results of the study. However,
without limiting our interview to those who had undergone
cataract extraction (and excluding anyone with posterior
capsular opacification), it would be extremely difficult to
overcome this limitation in this age group. Moreover, only
four participants had LOCS III scores of ‘2’ or higher
(three participants bilaterally for nuclear colour and one
participant unilaterally for posterior subcapsular cataract);
none of these participants used any descriptors that had
not been used by other participants with more negligible
lens opacities.
Other limitations of our study are worth noting. Partici-
pants were asked to view the NEI image with their own
spectacles if worn for near. There is the chance that discrep-
ancies between best-corrected subjective VA and habitual
near VA could have affected the way in which the NEI
image was perceived. However, our recruitment method
meant that all participants were motivated individuals and
likely to be proactive in their own eye care (for example,
wearing up-to-date spectacle prescriptions). There is no
evidence that wearing progressive (rather than single
vision) spectacle lenses to view the image was a factor in
the perception of peripheral parts of the image; no partici-
pant reported peripheral distortion on the NEI image. Fur-
thermore, participants were allowed and indeed
encouraged to hold the NEI image at an optimal viewing
distance and angle to allow ideal viewing conditions and
mitigate any perceptual distortion. The NEI image was
viewed binocularly in order to replicate habitual vision for
participants. However, we permitted fellow eyes to be of
any AMD status, and graded severity of AMD according to
the better-seeing eye because the better eye is believed to
have a greater impact on vision-related quality of life than
the worse eye.14–16 Of course, this study does not assess
vision-related quality of life, rather it assesses visual
descriptors for dry AMD, for which the contribution of
better eye and worse eye may not be equivalent. Future
work might assess the impact of each eye’s visual symptoms
on binocular descriptions of vision in dry AMD.
Another key limitation is our small sample size. Our esti-
mates of people’s response to the picture are also restricted
because it was deemed inappropriate to show some partici-
pants the photograph if they had already expressed emo-
tional distress about their vision. Moreover, two
participants were unable to see the photograph due to poor
vision. It is certainly possible that these two participants
could have similar visual symptoms to that depicted in the
NEI image. Also, we limited our sample of participants to
those with VA better than 0.7 logMAR (Snellen 6/30, 20/
100); perhaps for AMD patients with worse VA, possibly as
a result of end stage GA, the NEI image is representative of
how they see. This is untested and would have to be the
subject of a different study design. Despite these limitations
surrounding the sample of people interviewed, the
© 2017 The Authors. Ophthalmic and Physiological Optics published by John Wiley & Sons Ltd on behalf of College of Optometrists.6
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experimental effect supporting the hypothesis that typical
images do not accurately depict visual symptoms for AMD
was very large. For instance, and loosely speaking, the lower
bound for our 95% confidence interval (53%) at least infers
one half of all people with dry AMD, as represented by our
sample, would likely reject the image in a wider population.
To conclude, images currently used to represent vision in
AMD are unrealistic for many people with dry AMD of
varying severities. A wide range of descriptors are used to
describe vision loss in dry AMD, indicating that vision loss
in this condition may manifest itself in a variety of ways.
These descriptions could be used to educate people about
the range of possible symptoms of dry AMD and are a step
towards building simulations of the view of AMD through
the patient’s eyes. In turn this might lead to better recogni-
tion of symptoms for people with and without the condi-
tion. The results from our study certainly suggest a need to
develop more realistic images of the visual symptoms of
AMD for patient and public education.
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